EBITDA

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

Fate Therapeutics' latest data suggests its iPSC-derived CAR-T could revolutionize lupus care, moving cell therapy beyond cancer and into the mainstream.

Toshiba partners with a 38-year local veteran in Trinidad & Tobago. We analyze the strategy behind a deal that's more than just printers—it's a play for an entire region.

A new wave of affordable, user-friendly robots is here. A new mower ditches complexity, but what are the strategic trade-offs for consumers and the market?

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

A deepening corporate governance battle pits STAAR Surgical's board against its largest shareholder and all major proxy firms over a $1.5B Alcon deal.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

Onex cashes out of Ryan Specialty with a stunning 49% IRR. We dive into the strategy behind the $1.2B exit and what it signals for specialty insurance.

EyeYon Medical's synthetic corneal implant, EndoArt, just got FDA approval for U.S. trials, offering a fix for the global donor tissue shortage.

As CEO J.K. Symancyk prepares for a key investor conference, Signet Jewelers' new strategy faces the test of a market transformed by tech and ethics.

ATI Inc. names operational veteran Rob Foster as its new CFO, signaling a strategic bet that manufacturing prowess is the key to financial success.

For 14 straight years, Hamilton Lane has been a 'Best Place to Work.' We analyze why this cultural consistency is its most potent strategic asset.

With advanced ZK tech and a key exchange partnership, Mantle is positioning itself as the institutional-grade bridge between Wall Street and tokenized assets.

A record-breaking tech award reveals a new map of global opportunity, data-driven trends, and a masterclass in strategic brand building from inDrive.

The future of boating isn't just in showrooms. It's in garages where DIYers are driving a quiet, clean-energy revolution on the water. Here's how.

Lumen Technologies is overhauling its balance sheet. Is this a savvy move for AI dominance or a risky gamble for the recovering telecom giant?

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

Monaghan Medical just won its 10th Zenith Award, voted on by clinicians. We unpack the strategy behind their decade of dominance in respiratory tech.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

Beyond the $1.2B price tag, Infinity's deal reveals a masterclass in energy M&A, strategic partnerships, and the consolidation of America's shale plays.